Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (OP:SKYE)

N/A UNCHANGED
Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 3 Next >
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Exposures Product Safety
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January. 
Via Benzinga
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Topics Derivatives Intellectual Property
Exposures Derivatives Intellectual Property
Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Topics Derivatives
Exposures Derivatives
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial... 
Via Benzinga
Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
- Recruitment for cohort 1 has begun- ... 
Via Newsfile
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Topics Cannabis
Exposures Cannabis Product Safety
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
San Diego, California--(Newsfile Corp. - September 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Topics Derivatives
Exposures Derivatives
Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has... 
Via Benzinga
Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company")... 
Via Newsfile
Emerald Health Therapeutics Shareholders Vote in Favour of Plan of Arrangement with Skye Bioscience
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC).   Mechoulam later also elucidated... 
Via Benzinga
Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer
Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing... 
Via Benzinga
Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc. 
Via Benzinga
Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to... 
Via Newsfile
Topics Derivatives
Exposures Derivatives
Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
Skye Bioscience, Inc. (OTCQB:SKYE) has entered into... 
Via Benzinga
Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc. 
Via Benzinga
These OTC Securities Had the Most Trading Activity in June
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
CEO Presenting on the Emerging Growth Conference on June 9. Register here
Niche Companies in Technology, Biotech, Precious Metals, and more in Attendance 
Via EIN Presswire
Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021
LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be... 
From Stock News Now
Via AccessWire
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.